Earnings quality
Compare earnings and operating cash flow for earnings quality.
Samsung Biologics Co., Ltd.
Ticker 207940 Β· π°π· Korea Β· Consolidated K-IFRS Β· amounts in won
Filed 2025-03-31 Β· Period end 2024-12-31
Takeaway
Dig deeperThe numbers send mixed signals β dig into cash flow and leverage before drawing a conclusion.
equity ratio is 62.9%.
Mixed signals β use cash flow and the balance sheet before treating the year as clean.
ActionDig deeper
OP marginβ
Equity ratio62.9%
Last priceβ
Trailing P/Eβ
Look at next
- Compare operating cash flow to reported profit across the last two years.
- Open English IR for management commentary on outlook and capital allocation.
- Overlay peers on Compare before judging relative momentum.
About the company
Samsung Biologics Co., Ltd. is a Korea-listed company with consolidated financial statements filed on DART (Open DART).
Financial statements
Income statement
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Revenue | β©3.7T | β©4.5T |
| Cost of sales* | β | β |
| Gross profit | β | β |
| Operating profit | β | β |
| Finance income | β | β |
| Finance costs | β | β |
| Income tax | β | β |
| Profit for the period | β | β |
| Profit to owners | β | β |
| Basic EPS | β | β |
Balance sheet
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Cash & equivalents | β©367.9B | β©391.2B |
| Current assets | β©5.5T | β©5.5T |
| Non-current assets | β©10.5T | β©11.8T |
| Total assets | β©16.0T | β©17.3T |
| Current liabilities | β©4.2T | β©3.9T |
| Short-term borrowings | β | β |
| Non-current liabilities* | β©2.1T | β©2.6T |
| Total liabilities | β©6.2T | β©6.4T |
| Ownersβ equity | β©9.8T | β©10.9T |
| Total equity | β©9.8T | β©10.9T |
Cash flow statement
| Account | FY2023 (ended Dec 31, 2023) | FY2024 (ended Dec 31, 2024) |
|---|---|---|
| Operating cash flow | β©1.7T | β©1.7T |
| Investing cash flow | -β©1.6T | -β©1.2T |
| Financing cash flow | -β©635.0B | -β©433.8B |
| Net change in cash | -β©535.1B | -β©18.3B |
| Cash at end of period | β©367.9B | β©391.2B |
Five-year trends
Key metrics
| Metric | Trend | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Revenue | β©1.2T | β©1.6T | β©3.0T | β©3.7T | β©4.5T | |
| Operating profit | β©292.8B | β©537.3B | β©983.6B | β©1.1T | β©1.3T | |
| Profit to owners | β©241.0B | β©393.6B | β©798.1B | β©857.7B | β©1.1T | |
| Total assets | β©6.4T | β©8.0T | β©16.6T | β©16.0T | β©17.3T | |
| Cash & equivalents | β©28.9B | β©47.4B | β©890.8B | β©367.9B | β©391.2B | |
| Ownersβ equity | β©4.6T | β©5.0T | β©9.0T | β©9.8T | β©10.9T |
How we read these numbers
From the notes
No material one-offs extracted from this filing.
Mixed
The numbers send mixed signals β dig into cash flow and leverage before drawing a conclusion.
On the income statement, revenue moved from β©3.7T to β©4.5T (β² +23.1%). Operating profit went from β to β (β).
Operating cash flow was β©1.7T (prior β©1.7T), with cash on the balance sheet at β©391.2B versus β©367.9B.
Liquidity & leverage
Watch short-term liabilities against the cash balance.
Capital buffer
Total equity moved from β©9.8T to β©10.9T.
Was this page helpful?
Source: DART 20250814004283
(μΌμ±λ°μ΄μ€λ‘μ§μ€(μ£Ό)), period end 2024-12-31.